跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Apidra - Philippines FDA Drug Approval Details
Approvals
/
Philippines FDA
/
Apidra
Approved
STANDARD
Apidra
Sanofi-Aventis Deutschland GmbH
🇵🇭 Food and Drug Administration - Philippines
Approval Date
Jul 14, 2025
Approval ID
cc2c3c4f44f43f15
Company
Sanofi-Aventis Deutschland GmbH
Type
Standard
Approval Details
Approval Id
cc2c3c4f44f43f15
Drug Approval Philippines Name
Apidra
Product Name
Apidra
Registration Number
BR-1046
Brand Name
Apidra
Generic Name
Insulin Glulisine
Dosage Form
Solution for Subcutaneous/Continuous SC Pump Infusion/ Intravenous Injection
Dosage Strength
3.49 mg/mL (equivalent to 100 Units/mL)
Manufacturer
Sanofi-Aventis Deutschland GmbH
Importer
Sanofi-Aventis Philippines, Inc.
Distributor
Sanofi-Aventis Philippines, Inc.
Company Detail Path
/organization/sanofi-aventis-deutschland-gmbh
Issuance Date
26 February 2021
Expiry Date
28 October 2025
Classification
Prescription Drug (RX)
Active Ingredients
Approved
Quick Info
Agency
Philippines FDA
Country
🇵🇭
Approval Date
Jul 14, 2025
Approval ID
cc2c3c4f44f43f15
Type
Standard
Back to Philippines FDA Approvals